Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H1 2018

February 2018 | 33 pages | ID: CC4C842D66AEN
Global Markets Direct

Abstracts

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H1 2018

SUMMARY

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Pancreatic Cancer, Leukemias, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Blood Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Cell Division Cycle 7 Related Protein Kinase - Pipeline Review, H1 2018, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
• The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Overview
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Eli Lilly and Co
Millennium Pharmaceuticals Inc
Nerviano Medical Sciences Srl
Sierra Oncology Inc
Takeda Pharmaceutical Co Ltd
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles
LBS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3143921 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSK-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDC7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDC7 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRA-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-931 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Products
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products
Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Feb 06, 2018: Sierra Oncology to host program update on SRA141 on February 27th in New York
Aug 23, 2017: Cancer Research UK launches trial to test new drug in patients with advanced cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Sierra Oncology Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

COMPANIES MENTIONED

Eli Lilly and Co
Millennium Pharmaceuticals Inc
Nerviano Medical Sciences Srl
Sierra Oncology Inc
Takeda Pharmaceutical Co Ltd